872857-95-9

Upstream product

• 39900-63-5 2-cyano-4-methoxyphenol 
• 1191044-96-8 3-bromo-2-hydroxy-5-methoxy-benzonitrile 
• 74-88-4 methyl iodide 
• 872857-94-8 3-bromo-2,5-dimethoxy-benzamide 

Downstream Products

• 872857-90-4 2,5-dimethoxy-3-trimethylstannanyl-benzonitrile 
• 1191044-97-9 2,5-dimethoxy-3-(4-methoxy-phenylethynyl)-benzonitrile 
• 1191044-95-7 5-hydroxy-2-(4-hydroxy-phenyl)-3-phenyl-benzofuran-7-carbonitrile 
• 1191044-99-1 5-methoxy-2-(4-methoxy-phenyl)-3-phenyl-benzofuran-7-carbonitrile 
• 1191044-98-0 3-iodo-5-methoxy-2-(4-methoxy-phenyl)-benzofuran-7-carbonitrile 

Relevant academic research and scientific papers

NOVEL ESTROGEN RECEPTOR LIGANDS

The invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt: wherein R3 is selected from the group consisting of ORA; -CHO; -C(O)C1-4alkyl; -C(O)phenyl; -O-C(O)RA; and N(RB)2; R6 is selected from certain cyclic groups defined in the specification; and the remaining groups are defined in the specification; together with a pharmaceutically acceptable carrier. Most of the compounds are novel. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

Tetracyclic compounds as estrogen ligands

This invention provides estrogen receptor modulators having the structure: wherein R1, R2, R3, R4, Q, n, R8, R9, R10, and R11 have been defined in the specification; o